A Genco1, I Ernesti2, R Ienca2, G Casella3, S Mariani2, D Francomano2, E Soricelli3, M Lorenzo4, M Monti3. 1. Department of Surgical Sciences, Surgical Endoscopy Unit, Sapienza University of Rome, Rome, Italy. alfredo.genco@uniroma1.it. 2. Department of Experimental Medicine-Medical Physiopathology, Food Science and Endocrinology Section, Sapienza University of Rome, Rome, Italy. 3. Department of Surgical Sciences, Surgical Endoscopy Unit, Sapienza University of Rome, Rome, Italy. 4. National Health Service, Naples, Italy.
Abstract
PURPOSE: The aim of this study was to evaluate the safety and efficacy of a new intragastric balloon (Elipse™ Balloon, Allurion Technologies, Natick, MA USA) not needing endoscopy. MATERIALS AND METHODS: The balloon was swallowed under fluoroscopy in 38 consecutive patients (F/M 28/10, mean age 46.4 ± 10.6 years, mean weight 109.7 ± 21.9 kg, and mean body mass index (BMI) 38.6 ± 6.7 kg/m2). After 4 months, the balloon spontaneously emptied and it was excreted through the digestive tract without upper endoscopy. RESULTS: There were no complications during balloon passage. After 16 weeks, the mean weight loss was 12.7 kg, mean percent excess weight loss was 26%, and mean BMI reduction was 4.2 kg/m2. Total body weight loss was 11.6%. There was a significant reduction in major co-morbidities related to metabolic syndrome: blood pressure (p < 0.02), waist circumference (p < 0.002), triglycerides (p < 0.0001), blood glucose (p < 0.001), and HOMA-IR index (p < 0.001). At the end of the treatment, 37 balloons were naturally excreted in the stool, and one balloon was endoscopically removed. CONCLUSIONS: The results of this study on 38 consecutive patients demonstrate that the Elipse™ Balloon is safe, effective, and very well accepted by patients.
PURPOSE: The aim of this study was to evaluate the safety and efficacy of a new intragastric balloon (Elipse™ Balloon, Allurion Technologies, Natick, MA USA) not needing endoscopy. MATERIALS AND METHODS: The balloon was swallowed under fluoroscopy in 38 consecutive patients (F/M 28/10, mean age 46.4 ± 10.6 years, mean weight 109.7 ± 21.9 kg, and mean body mass index (BMI) 38.6 ± 6.7 kg/m2). After 4 months, the balloon spontaneously emptied and it was excreted through the digestive tract without upper endoscopy. RESULTS: There were no complications during balloon passage. After 16 weeks, the mean weight loss was 12.7 kg, mean percent excess weight loss was 26%, and mean BMI reduction was 4.2 kg/m2. Total body weight loss was 11.6%. There was a significant reduction in major co-morbidities related to metabolic syndrome: blood pressure (p < 0.02), waist circumference (p < 0.002), triglycerides (p < 0.0001), blood glucose (p < 0.001), and HOMA-IR index (p < 0.001). At the end of the treatment, 37 balloons were naturally excreted in the stool, and one balloon was endoscopically removed. CONCLUSIONS: The results of this study on 38 consecutive patients demonstrate that the Elipse™ Balloon is safe, effective, and very well accepted by patients.
Entities:
Keywords:
Elipse™; Intragastric balloon; Overweight/obese treatment; Weight loss
Authors: A Genco; M Cipriano; V Bacci; M Cuzzolaro; A Materia; L Raparelli; C Docimo; M Lorenzo; N Basso Journal: Int J Obes (Lond) Date: 2006-01 Impact factor: 5.095
Authors: Jaime Ponce; George Woodman; James Swain; Erik Wilson; Wayne English; Sayeed Ikramuddin; Eric Bour; Steven Edmundowicz; Brad Snyder; Flavia Soto; Shelby Sullivan; Richard Holcomb; John Lehmann Journal: Surg Obes Relat Dis Date: 2014-12-16 Impact factor: 4.734
Authors: A Genco; T Bruni; S B Doldi; P Forestieri; M Marino; L Busetto; C Giardiello; L Angrisani; L Pecchioli; P Stornelli; F Puglisi; M Alkilani; A Nigri; N Di Lorenzo; F Furbetta; A Cascardo; M Cipriano; M Lorenzo; N Basso Journal: Obes Surg Date: 2005-09 Impact factor: 4.129
Authors: Iñaki Imaz; Carmen Martínez-Cervell; Elvira Elena García-Alvarez; Juan Manuel Sendra-Gutiérrez; Jesús González-Enríquez Journal: Obes Surg Date: 2008-05-06 Impact factor: 4.129
Authors: Evzen Machytka; Ram Chuttani; Martina Bojkova; Tomas Kupka; Marek Buzga; Kathryn Stecco; Samuel Levy; Shantanu Gaur Journal: Obes Surg Date: 2016-03 Impact factor: 4.129
Authors: Evzen Machytka; Shantanu Gaur; Ram Chuttani; Martina Bojkova; Tomas Kupka; Marek Buzga; Andreas Giannakou; Kandiliotis Ioannis; Elisabeth Mathus-Vliegen; Samuel Levy; Ioannis Raftopoulos Journal: Endoscopy Date: 2016-12-12 Impact factor: 10.093
Authors: R Ienca; C Giardiello; A Scozzarro; R Schiano di Cola; N Di Lorenzo; Girish Juneja; G Lopez; F Badiuddin Journal: Obes Surg Date: 2019-09 Impact factor: 4.129
Authors: Luigi Schiavo; Giovanni De Stefano; Francesco Persico; Stefano Gargiulo; Federica Di Spirito; Giulia Griguolo; Niccolò Petrucciani; Eric Fontas; Antonio Iannelli; Vincenzo Pilone Journal: Obes Surg Date: 2020-11-20 Impact factor: 4.129